Inspire Veterinary Partners filings document the public-company record for a Nevada issuer operating in U.S. veterinary and pet health care services. The record includes Form 8-K reports on exchange-listing status, material agreements, amendments to authorized Class A common stock, board changes, and other corporate governance matters.
Registration statements describe securities offerings and issuer classifications, while late-filing notices and Form 15 documentation address periodic reporting status under the Securities Exchange Act. The filings also cover Class A common stock, capital-structure changes, OTCQB trading following Nasdaq delisting, and the company’s formal suspension or termination of Exchange Act reporting duties.
Armistice Capital, LLC and Steven Boyd report a 9.99% beneficial stake in Inspire Veterinary Partners, Inc. The Schedule 13G/A shows Armistice Capital (Delaware) and Steven Boyd (U.S.) collectively beneficially own 228,584 shares of Class A common stock (CUSIP G0360L134). The filing attributes shared voting and dispositive power over all 228,584 shares and reports no sole voting or dispositive power. The reporting parties say the shares are held in the ordinary course of business and not to influence control. The statement notes the Master Fund is the direct holder and Armistice Capital acts as investment manager.
Anne Murphy, identified as a director of Inspire Veterinary Partners, Inc. (ticker: IVP), reported a derivative security transaction on Form 4. The filing discloses an acquisition dated 09/26/2024 of a stock option (right to buy) covering 1,447 shares of Class A common stock with an exercise price of $17 per share. The options are shown as exercisable on 09/26/2024 and expiring on 09/26/2034, and the reported post-transaction beneficial ownership is 1,447 shares held directly.
The form notes that reported share counts have been adjusted for a 25-for-1 reverse stock split effected on 01/27/2025. The filing states it was submitted late due to an "inadvertent administrative error" and is signed by Anne Murphy with a signature date of 08/08/2025.
Inspire Veterinary Partners, Inc. disclosed that holders of a majority (78.4%) of its voting power approved, by written consent dated July 24, 2025, a Private Placement consisting of (i) a Securities Purchase Agreement (July 28, 2025) providing for up to $10.0 million of Series B convertible preferred stock and accompanying warrants and (ii) a Common Stock Purchase Agreement (ELOC Agreement, July 29, 2025) under which an accredited investor may purchase up to $50.0 million of Common Stock. The Company completed an initial closing on July 29, 2025, issuing 6,340 shares of Series B preferred stock and 6,340,000 warrants for approximately $6.0 million in proceeds.
The warrants have a five-year term and an initial $1.00 exercise price, with conversion and exercise prices subject to downward adjustment but floored near $0.1876–$0.1879. Series B conversions and ELOC purchases are subject to beneficial ownership limits (generally 4.99%) and Nasdaq listing rules; the Majority Stockholders’ approval was obtained to permit issuances that would otherwise exceed Nasdaq’s Exchange Cap. The Series B terms include covenants restricting dividends, repurchases and certain indebtedness and require the Company to reserve significant authorized shares to satisfy conversions, all of which may materially dilute existing holders and affect voting/economic interests.
Lawrence Alexander, a director of Inspire Veterinary Partners, reported acquiring stock options that give the right to purchase 1,447 shares of Class A Common Stock at an exercise price of $17. The options were recorded with a transaction date of 09/26/2024, are exercisable on 09/26/2024 and expire on 09/26/2034, and are held in a direct ownership form.
The filing notes a corporate action that adjusted reported share counts: the issuer effected a 25-to-1 reverse stock split on 01/27/2025, and the numbers on this Form 4 were updated to reflect that split. The report shows 1,447 options outstanding following the transaction, representing the right to buy 1,447 Class A shares at the stated price until 2034.
Charles Stith Keiser, a director of Inspire Veterinary Partners, Inc. (IVP), reported exercising stock options on 09/26/2024 to acquire 953 shares of Class A Common Stock at an exercise price of $17 per share. The transaction is reported as a direct acquisition and the Form 4 notes that the share amounts have been adjusted for a 25-for-1 reverse stock split effected by the issuer on January 27, 2025. The filing states it was submitted late due to an inadvertent administrative error and is signed by Mr. Keiser on 08/07/2025.
Frank Richard, Chief Financial Officer of Inspire Veterinary Partners, Inc. (IVP), acquired 58,480 stock options on 04/01/2025. The options carry a $1.71 exercise price, are exercisable on 04/01/2025 and expire 04/01/2035, each covering one Class A common share. The reported ownership is direct. The Form 4 notes the filing was late due to an inadvertent administrative error and is signed 08/06/2025.
Kimball Carr, Chief Executive Officer, President and Chair acquired 92,593 Class A common shares by exercising stock options with a $1.62 exercise (conversion) price on 05/16/2025. The options were exercisable on 05/16/2025 and expire 05/16/2035. Following the reported transaction, 92,593 shares are beneficially owned directly. Remarks state the Form 4 was filed late due to an inadvertent administrative error.
INSPIRE Veterinary Partners officer Kees Lynley acquired 34,247 stock options exercisable immediately on 05/28/2025 with an exercise price of $1.52. Each option converts into one share of Class A Common Stock and the options expire on 05/28/2035. Following the transaction, the reporting person directly beneficially owns 34,247 derivative securities.
Inspire Veterinary Partners, Inc. (IVP) reported an initial Form 3 for Kees Lynley, who is identified as the company's Chief People Officer and a director/officer. The filing states that no securities are beneficially owned by the reporting person and notes the Form 3 was filed late due to an inadvertent administrative error.
Inspire Veterinary Partners (Nasdaq: IVP) filed an 8-K disclosing two capital-raising arrangements that could supply up to $60 million of new funding but introduce meaningful dilution.
On 28-29 Jul 2025 the company signed a Securities Purchase Agreement for a private placement of up to 7,590 Series B convertible preferred shares (stated value $1,000) plus equal-number warrants. At the first closing investors bought 6,340 preferred shares and 6,340,000 five-year warrants for $5 million. The preferred converts at $1.00 per share (floor $0.1876) and the warrants initially exercise at $1.00, both subject to reset on lower-priced issuances. The stock ranks senior to all other equity, has no voting rights, and carries standard anti-dilution, redemption (125% premium) and change-of-control protections. The company must reserve 250 % of the shares needed for conversion and file a resale registration statement.
Separately, IVP entered a $50 million committed equity line with a single accredited investor. IVP may, at its option, sell up to $5 million of common stock per notice when the market price is ≥$0.75, subject to a 4.99 % ownership cap. Proceeds are earmarked for working capital. Either party can terminate under customary default, delisting or bankruptcy triggers.
- Aggregate potential raise: $60 million
- Immediate cash received: ~$5 million
- Maximum dilution: variable; conversion and warrant floors set at ~$0.19